Regeneron to advance two factor xi antibodies into a broad phase 3 program following positive phase 2 proof-of-concept results

Investigational regn7508 (catalytic domain) and regn9933 (a2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings

REGN Ratings Summary

REGN Quant Ranking